The GlioME Team has new publication out in International Journal of Molecular Sciences as part of the Special Issue « Emerging Therapies for Glioblastoma ». This article deals with one of the team’s key issues, the gangliosides recognized by the A2B5 antibody and used as biomarker of cancer stem cells (CSC) in glioblastoma human brain tumours. To tackle these CSC known to be resistant to conventional treatment, the GlioME team aimed to better understand the effect of neuraminidase administration that removes A2B5, on an organotypic three-dimensional glioblastoma model. Results demonstrate that, by its pleiotropic action, neuraminidase is an attractive local treatment against glioblastoma.
Read the article here: https://www.mdpi.com/1422-0067/24/14/11645
PDF Version: https://www.mdpi.com/1422-0067/24/14/11645/pdf
